| Objective: By observing and comparing such variables as occurrence rate, degree of severity and the minimum exposure to dermatitis, the researcher attempts to observe the clinical effect of Liangxue Jiedu Gao in preventing and treating radioactive dermatitis, thus in the hope of providing an insight into clinical prevention of radioactive dermatitis.Methods: The current open-label study was designed to evaluate the effect.The subjects(40 patients with nasopharyngeal carcinoma(NPC); 40 patients with breast cancer(BC); 100 patients with esophageal cancer(EPC)and 100 patients with lung cancer(LC))were randomly divided into two groups: experimental group and control group and were given Liangxue Jiedu Gao and conventional treatment respectively. Conventional treatment adopted by the control group prevents and treats radioactive dermatitis by cleaning damaged skin with sterile saline to keep the infected area dry and clean, in combination with conventional radiotherapy and providing relevant health education put altogether. In experimental group,the patients, besides conventional treatment as mentioned above,were given Liangxue Jiedu Gao also, which was applied on the affected skin 3 times a day successively. Degree of severity and frequency and minimum radiation dose,degree of pain and adverse drug reaction will be observed and compared.RTOG Standard adopted in 1995 and NRS 10 classification method were used to determine the degree of radioactive dermatitis and the pain degree.The results were compared and statistically analyzed by SPSS13.0 by T-test, F test,RIDIT test and x2 test.Results:1 There are no statistical differences in gender, age, clinical stage,pathological classification, irradiation dose and Carr’s score(P>0.05) in fourdifferent groups of cancer patients.2 There are no statistical differences in occurrence rate(both 100%)among patients with nasopharyngeal carcinoma(NPC)(P>0.05),while there are differences in radioactive dermatitis incidence and the differences are significant at 0.05 level among patients with nasopharyngeal carcinoma(NPC) at Mild Level(LevelsⅠ + Levels Ⅱ) and Moderate Level(Level Ⅲ)(P<0.05).There are no statistical differences in occurrence rate(both 100%) among patients with breast cancer(BC)(P > 0.05),while there are differences in radioactive dermatitis incidence and the differences are significant at 0.05 level among patients with breast cancer(BC) at Mild Level(LevelsⅠ +Levels Ⅱ) and Moderate Level(Level Ⅲ)(P<0.05).Patients with esophageal cancer(EPC) show differences(82% and 96%respectively in experimental group and control group) and the difference was statistically significant(P<0.05). Differences in Mild Level(LevelsⅠ+ Levels Ⅱ) and Moderate Level(Level Ⅲ) patients are significant in terms of radioactive dermatitis incidence(P<0.05).Patients with Lung cancer(LC) show differences( 78% and 92%respectively in experimental group and control group) and the difference was statistically significant(P<0.05). Differences in Mild Level(LevelsⅠ+ Levels Ⅱ) and Moderate Level(Level Ⅲ) patients are significant in terms of radioactive dermatitis incidence(P<0.05).Statistically, there are statistical differences among 280 patients in the overall occurrence rate of radioactive dermatitis, 85.7% for experimental group and 95.7% for the control group(P<0.05).3 Radiation dose in each groups of patients with radioactive dermatitisThere are statistical differences in radiation dose among patients with nasopharyngeal carcinoma(NPC) between two groups before 40 Gy exposure(6 in experimental group while 19 in the control group)(P<0.05)and after Gy exposure( 14 in experimental group while and 1 in the control group)( P<0.05).There are statistical differences in radiation dose among patients with breast cancer(BC) between two groups before 25 Gy exposure(12 in experimental group while 20 in the control group)(P<0.05)and after 25 Gy exposure( 8 in experimental group while and 0 in the control group)( P<0.05).There are statistical differences in radiation dose among patients with esophageal cancer(EPC) between two groups before 40 Gy exposure(10 in experimental group while 34 in the control group)(P<0.05)and after 40 Gy exposure( 31 in experimental group while and 14 in the control group)(P<0.05).There are statistical differences in radiation dose among patients with lung cancer(LC) between two groups before 40 Gy exposure(10 in experimental group while 19 in the control group)(P<0.05)and after 40 Gy exposure( 29 in experimental group while and 25 in the control group)(P<0.05).4 Comparison of pain degrees among patients with radioactive dermatitisThere are statistical differences in pain degrees among patients with nasopharyngeal carcinoma(NPC) : 11, 9 and 0 cases rated as Degree1-3,4-6 and 7-9 according to NRS Classification standard in experimental group versus 5,14 and 1 in control group respectively(P<0.05)There are statistical differences in pain degrees among patients with esophageal cancer(EPC) : 28, 13 and 0 cases rated as Degree 1-3,4-6and 7-9 according to NRS Classification standard in experimental group versus 18,30 and 0 in control group respectively(P<0.05)There are statistical differences in pain degrees among patients with lung cancer(LC) : 20, 19 and 0 cases rated as Degree 1-3,4-6 and 7-9according to NRS Classification standard in experimental group versus 15,31 and 0 in control group respectively(P<0.05)Conclusions:1 Liangxue Jiedu Gao can reduce the incidence of radioactive dermatitis,thus reducing radiation damage to the skin and preventing moderate–leveland severe –level radioactive dermatitis.2 Liangxue Jiedu Gao can improve the skin tolerance in radiation therapy in patients’ ray irradiation area, and delay the onset of radioactive dermatitis.3 Liangxue Jiedu Gao can relieve the pain caused by radioactive dermatitis felt by patients with nasopharyngeal carcinoma, esophageal cancer, breast cancer, lung cancer.4 Head and neck skin, compared with the skin in the chest and back, has lower tolerance to ray radiation. The chance of infecting radioactive dermatitis in patients with nasopharyngeal carcinoma is higher than that in patients with esophageal cancer and lung cancer. |
PDF Full Text Request